Gilead Sciences, US3755581036

Gilead Sciences stock: TD Cowen keeps $175 target

Published on 11/20/2026 at 16:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
TD Cowen reaffirmed its Buy rating on November 18 as Yeztugo prescriptions strengthened. Gilead Sciences stock now hinges on sustained HIV prevention growth.

Yeztugo growth becomes the test

  • TD Cowen linked its reiterated Buy rating to stronger Yeztugo demand.
  • Gilead's HIV prevention portfolio must keep expanding as future Biktarvy pricing pressure approaches.
  • Prescription momentum and upcoming regulatory milestones will shape the next investor debate.
Gilead Sciences, US3755581036, Illustration mit AI erstellt.

On Wednesday, November 18, TD Cowen reiterated its Buy rating on Gilead Sciences and kept a price target of 175 US dollars. The brokerage cited stronger Yeztugo performance, according to Investing.com.

Yeztugo demand supports the rating

TD Cowen said monthly Yeztugo injection prescriptions rose 9 percent in October from the previous month. The firm estimates fourth-quarter US sales of 367 million US dollars, above its 359 million US dollar consensus estimate.

The brokerage also lifted its full-year Yeztugo sales estimate to about 1.1 billion US dollars from 1 billion US dollars previously. That forecast is above both the 1 billion US dollar consensus estimate and Gilead's guidance. Third-quarter Yeztugo sales were 305 million US dollars, while patient persistence exceeded 70 percent, according to the report.

Prevention offsets a pricing risk

Yeztugo is becoming a central part of Gilead's HIV prevention strategy as the company prepares for future pricing pressure on Biktarvy. The prevention portfolio's growth is therefore important for the company's effort to expand HIV revenue beyond its established treatment franchise.

Investors will also watch the regulatory path for a once-weekly oral version of Yeztugo. The next major readouts are expected to test whether demand remains strong as the product broadens its commercial reach.

Investor focus shifts to execution

The TD Cowen view places prescription trends and launch execution ahead of a single clinical milestone. For Gilead, sustained prevention growth could strengthen the response to longer-term pricing pressure, while weaker uptake would leave the business more exposed to its largest HIV products.

Gilead Sciences at a glance

  • Company: Gilead Sciences, Inc.
  • ISIN: US3755581036
  • Ticker: GILD
  • Home exchange: Nasdaq

The broader US equity market remains the backdrop for Gilead Sciences stock. Current market reports provide wider market context.

More news and analyses on Gilead Sciences stock

Disclaimer...
en | US3755581036 | GILEAD SCIENCES | boerse | 70540521 | bgmi